Publications by authors named "Cynthia Bender"
Acute lymphoblastic leukemia (ALL) is a heterogenous hematological malignancy representing 25% of all cancers in children less than 15 years of age. Significant improvements in survival and cure rates have been made over the past four decades in pediatric ALL treatment. Asparaginases, derived from and , have become a critical component of ALL therapy since the 1960s.
View Article and Find Full Text PDFArticle Synopsis
- Asparaginase is key in treating pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy), but hypersensitivity to the PEGylated version, pegaspargase, is a common issue.
- Due to a shortage of the alternative erwinia asparaginase, researchers explored the use of a rapid desensitization protocol to allow safe administration of pegaspargase to patients with a history of hypersensitivity.
- In a study with ten patients, eight achieved therapeutic levels of asparaginase, and five received multiple doses of pegaspargase without serious reactions, demonstrating the effectiveness of the desensitization approach.